Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022

Reflections on ESMO22

What really stood out from the oral presentations at ESMO this year?

September 16, 2022

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022

Sorting out confusion, confliction, and confounding results in clear cell RCC

How do we help more early stage ccRCC patients live long and prosper?

September 12, 2022

Time to change lines in breast cancer?

Round up ad discussion of key breast cancer trials in HR+/HER2- disease

September 11, 2022

Making your mind up

Are all PARP inhibitors the same?

September 10, 2022

ESMO22 Preview on Targeted Therapies in Developmental Therapeutics

New developments in early stage targeted therapy agents

September 6, 2022

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022

New controversies in GI malignancies

What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma

August 24, 2022

ESMO22 Preview 1 – what to watch out for in breast cancer

Review of some of the key trials in breast cancer being showcased in Paris next month

August 22, 2022